HYPR
What one share of Hyperfine holds
Electromedical and Electrotherapeutic Apparatus
We are an innovative health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (“AI”)-powered portable ultra-low-field (“ULF”) magnetic resonance (“MR”) brain imaging.
Hyperfine’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.18 |
|---|---|
| Profit | −$0.38 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.30 |
| Cash and investments | $0.44 |
| Debt | $0.13 |
| Book value | $0.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.19 | −$15.38 | $1.03 | −$15.16 | — | −$40.09 |
| 2021 | $0.41 | −$17.57 | $0.73 | −$13.52 | — | $50.46 |
| 2022 | $0.10 | −$1.04 | $0.01 | −$1.04 | — | $1.76 |
| 2023 | $0.15 | −$0.62 | $0.01 | −$0.60 | — | $1.18 |
| 2024 | $0.18 | −$0.56 | $0.01 | −$0.54 | — | $0.68 |
| 2025 | $0.17 | −$0.43 | $0.01 | −$0.36 | — | $0.50 |